December 13, 2002, the president of the United States announced that smallpox vaccination would be offered to some categories of civilians and administered to members of the military and government representatives in high-risk areas of the world. The events that precipitated that historic announcement included a series of terrorist attacks during the 1990s, which culminated in the catastrophic events of 2001.
Although preparedness for deliberate attacks with biologic weapons was already the subject of much public health planning, meetings, and publications as the twentieth century neared its end, the events of 2001 led to a steep rise in bioterrorism-related government policies and funding, and in state and local preparedness activities, for example, in public health, health care, and the emergency response and public safety communities. The national smallpox vaccination program is but one of many efforts to improve readiness to respond to deliberate releases of biologic agents.
The Institute of Medicine (IOM) Committee on Smallpox Vaccination Program Implementation was convened in October 2002 at the request of the Centers for Disease Control and Prevention (CDC), the federal agency charged with implementing the government's policy of providing smallpox vaccine first to public health and health care workers on response teams, then to all interested health care workers and other first responders, and finally to members of the general public who might insist on receiving the vaccine. The committee was charged with providing "advice to the CDC and the program investigators on selected aspects of the smallpox program implementation and evaluation."
The committee met six times over 19 months and wrote a series of brief "letter" reports. The Smallpox Vaccination Program: Public Health in an Age of Terrorism constitutes the committee's seventh and final report, and the committee hopes that it will fulfill three purposes: 1) To serve as an archival document that brings together the six reports addressed to Julie Gerberding, director of CDC, and previously released on line and as short, unbound papers; 2) To serve as a historical document that summarizes milestones in the smallpox vaccination program, and ; 3) To comment on the achievement of overall goals of the smallpox vaccination program (in accordance with the last item in the charge), including lessons learned from the program.
Table of Contents
|1 Smallpox and Smallpox Control in the Historical Context||9-21|
|2 Policy Context of Smallpox Preparedness||22-38|
|3 The Implementation of the Smallpox Vaccination Program||39-80|
|4 Lessons Learned from the Smallpox Vaccination Program||81-108|
|Appendix A: Recomendations from Letter Reports 1-6||109-122|
|Appendix B: Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation Letter Report #1||123-161|
|Appendix C: Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation Letter Report #2||162-194|
|Appendix D: Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation Letter Report #3||195-202|
|Appendix E: Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation Letter Report #4||203-251|
|Appendix F: Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation Letter Report #5||252-284|
|Appendix G: Review of the Centers for Disease Control and Prevention’s Smallpox Vaccination Program Implementation Letter Report #6||285-328|
|Appendix H: Agendas for Committee Information-Gathering Meetings||329-341|
|Appendix I: Committee Biosketches||342-348|
The National Academies Press (NAP) has partnered with Copyright Clearance Center's Rightslink service to offer you a variety of options for reusing NAP content. Through Rightslink, you may request permission to reprint NAP content in another publication, course pack, secure website, or other media. Rightslink allows you to instantly obtain permission, pay related fees, and print a license directly from the NAP website. The complete terms and conditions of your reuse license can be found in the license agreement that will be made available to you during the online order process. To request permission through Rightslink you are required to create an account by filling out a simple online form. The following list describes license reuses offered by the National Academies Press (NAP) through Rightslink:
Click here to obtain permission for the above reuses. If you have questions or comments concerning the Rightslink service, please contact:
Rightslink Customer Care
Tel (toll free): 877/622-5543
To request permission to distribute a PDF, please contact our Customer Service Department at 800-624-6242 for pricing.
To request permission to translate a book published by the National Academies Press or its imprint, the Joseph Henry Press, please click here to view more information.